China Life Private Equity Investment led a $79m Series A round in Huisheng Biopharmaceutical.

Synopsis

China Life Private Equity Investment, a private equity firm, led a $79m Series A round in Huisheng Biopharmaceutical, a biopharmaceutical company, with participation from Tianjin Grand Flight and Ginkgo Capital.

Principals

target

Huisheng Biopharmaceutical

bidder

Tianjin Grand Flight

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Market Context

ernst & young

HQ - London

accounting advisors

bidder

3797

Deals

£ 959.82 B

Total Value